Your browser doesn't support javascript.
loading
Genetic assessment of efficacy and safety profiles of coagulation cascade proteins identifies Factors II and XI as actionable anticoagulant targets.
Gagnon, Eloi; Girard, Arnaud; Bourgault, Jérôme; Abner, Erik; Gill, Dipender; Thériault, Sébastien; Vohl, Marie-Claude; Tchernof, André; Esko, Tõnu; Mathieu, Patrick; Arsenault, Benoit J.
Affiliation
  • Gagnon E; Centre de recherche de l'Institut universitaire de cardiologie et de pneumologie de Québec, Y-3106, Pavillon Marguerite D'Youville, 2725 chemin Ste-Foy, Quebec, QC, Canada, G1V 4G5.
  • Girard A; Centre de recherche de l'Institut universitaire de cardiologie et de pneumologie de Québec, Y-3106, Pavillon Marguerite D'Youville, 2725 chemin Ste-Foy, Quebec, QC, Canada, G1V 4G5.
  • Bourgault J; Centre de recherche de l'Institut universitaire de cardiologie et de pneumologie de Québec, Y-3106, Pavillon Marguerite D'Youville, 2725 chemin Ste-Foy, Quebec, QC, Canada, G1V 4G5.
  • Abner E; Centre de recherche de l'Institut universitaire de cardiologie et de pneumologie de Québec, Y-3106, Pavillon Marguerite D'Youville, 2725 chemin Ste-Foy, Quebec, QC, Canada, G1V 4G5.
  • Gill D; Department of Epidemiology and Biostatistics, School of Public Health, Imperial College London, London, UK.
  • Thériault S; Centre de recherche de l'Institut universitaire de cardiologie et de pneumologie de Québec, Y-3106, Pavillon Marguerite D'Youville, 2725 chemin Ste-Foy, Quebec, QC, Canada, G1V 4G5.
  • Vohl MC; Department of Molecular Biology, Medical Biochemistry and Pathology, Faculty of Medicine, Université Laval, Quebec, QC, Canada.
  • Tchernof A; School of Nutrition, Université Laval, Quebec, QC, Canada.
  • Esko T; Centre Nutrition, Santé et société (NUTRISS), Institut sur la nutrition et les aliments fonctionnels (INAF), Université Laval, Quebec, QC, Canada.
  • Mathieu P; Centre de recherche de l'Institut universitaire de cardiologie et de pneumologie de Québec, Y-3106, Pavillon Marguerite D'Youville, 2725 chemin Ste-Foy, Quebec, QC, Canada, G1V 4G5.
  • Arsenault BJ; School of Nutrition, Université Laval, Quebec, QC, Canada.
Eur Heart J Open ; 4(3): oeae043, 2024 May.
Article in En | MEDLINE | ID: mdl-38933427
ABSTRACT

Aims:

Anticoagulants are routinely used by millions of patients worldwide to prevent blood clots. Yet, problems with anticoagulant therapy remain, including a persistent and cumulative bleeding risk in patients undergoing prolonged anticoagulation. New safer anticoagulant targets are needed. Methods and

results:

To prioritize anticoagulant targets with the strongest efficacy [venous thromboembolism (VTE) prevention] and safety (low bleeding risk) profiles, we performed two-sample Mendelian randomization and genetic colocalization. We leveraged three large-scale plasma protein data sets (deCODE as discovery data set and Fenland and Atherosclerosis Risk in Communities as replication data sets] and one liver gene expression data set (Institut Universitaire de Cardiologie et de Pneumologie de Québec bariatric biobank) to evaluate evidence for a causal effect of 26 coagulation cascade proteins on VTE from a new genome-wide association meta-analysis of 44 232 VTE cases and 847 152 controls, stroke subtypes, bleeding outcomes, and parental lifespan as an overall measure of efficacy/safety ratio. A 1 SD genetically predicted reduction in F2 blood levels was associated with lower risk of VTE [odds ratio (OR) = 0.44, 95% confidence interval (CI) = 0.38-0.51, P = 2.6e-28] and cardioembolic stroke risk (OR = 0.55, 95% CI = 0.39-0.76, P = 4.2e-04) but not with bleeding (OR = 1.13, 95% CI = 0.93-1.36, P = 2.2e-01). Genetically predicted F11 reduction was associated with lower risk of VTE (OR = 0.61, 95% CI = 0.58-0.64, P = 4.1e-85) and cardioembolic stroke (OR = 0.77, 95% CI = 0.69-0.86, P = 4.1e-06) but not with bleeding (OR = 1.01, 95% CI = 0.95-1.08, P = 7.5e-01). These Mendelian randomization associations were concordant across the three blood protein data sets and the hepatic gene expression data set as well as colocalization analyses.

Conclusion:

These results provide strong genetic evidence that F2 and F11 may represent safe and efficacious therapeutic targets to prevent VTE and cardioembolic strokes without substantially increasing bleeding risk.
Key words

Full text: 1 Collection: 01-internacional Database: MEDLINE Language: En Journal: Eur Heart J Open Year: 2024 Document type: Article Country of publication: United kingdom

Full text: 1 Collection: 01-internacional Database: MEDLINE Language: En Journal: Eur Heart J Open Year: 2024 Document type: Article Country of publication: United kingdom